These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 37225014)

  • 1. J-shaped association between LDL cholesterol and cardiovascular events: A longitudinal primary prevention cohort of over 2.4 million people nationwide.
    Park CS; Yang HM; Han K; Lee HS; Kang J; Han JK; Park KW; Kang HJ; Koo BK; Kim HS
    J Adv Res; 2024 Apr; 58():139-147. PubMed ID: 37225014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.
    Rosenblit PD
    Curr Diab Rep; 2019 Nov; 19(12):146. PubMed ID: 31754844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of Low-density Lipoprotein Cholesterol Level-Guided Statin Treatment in Patients With Borderline Cardiovascular Risk.
    Kohli-Lynch CN; Bellows BK; Thanassoulis G; Zhang Y; Pletcher MJ; Vittinghoff E; Pencina MJ; Kazi D; Sniderman AD; Moran AE
    JAMA Cardiol; 2019 Oct; 4(10):969-977. PubMed ID: 31461121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of Incident Atherosclerotic Cardiovascular DiseaseEvents by Achieved Atherogenic Lipid Levels Among62,428 Statin-Treated Individuals With Diabetes Mellitus.
    Rana JS; Liu JY; Moffet HH; Boklage SH; Khan I; Karter AJ
    Am J Cardiol; 2018 Sep; 122(5):762-767. PubMed ID: 30057224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of Nontraditional Risk Markers in Individuals Ineligible for Statin Therapy According to the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines.
    Yeboah J; Polonsky TS; Young R; McClelland RL; Delaney JC; Dawood F; Blaha MJ; Miedema MD; Sibley CT; Carr JJ; Burke GL; Goff DC; Psaty BM; Greenland P; Herrington DM
    Circulation; 2015 Sep; 132(10):916-22. PubMed ID: 26224808
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Burden and predictors of statin use in primary and secondary prevention of atherosclerotic vascular disease in the US: from the National Health and Nutrition Examination Survey 2017-2020.
    Chobufo MD; Regner SR; Zeb I; Lacoste JL; Virani SS; Balla S
    Eur J Prev Cardiol; 2022 Oct; 29(14):1830-1838. PubMed ID: 35653373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relation of Cardiovascular Events and Deaths to Low-Density Lipoprotein Cholesterol Level Among Statin-Treated Patients With Atherosclerotic Cardiovascular Disease.
    Chamberlain AM; Cohen SS; Weston SA; Fox KM; Xiang P; Killian JM; Qian Y
    Am J Cardiol; 2019 Jun; 123(11):1739-1744. PubMed ID: 30948001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective examination of lipid-lowering treatment patterns in a real-world high-risk cohort in the UK in 2014: comparison with the National Institute for Health and Care Excellence (NICE) 2014 lipid modification guidelines.
    Steen DL; Khan I; Ansell D; Sanchez RJ; Ray KK
    BMJ Open; 2017 Feb; 7(2):e013255. PubMed ID: 28213597
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events.
    Zhan S; Tang M; Liu F; Xia P; Shu M; Wu X
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD012502. PubMed ID: 30480766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 2013 ACC/AHA Cholesterol Guideline and Implications for Healthy People 2020 Cardiovascular Disease Prevention Goals.
    Egan BM; Li J; White K; Fleming DO; Connell K; Hernandez GT; Jones DW; Ferdinand KC; Sinopoli A
    J Am Heart Assoc; 2016 Aug; 5(8):. PubMed ID: 27543306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial.
    Giugliano RP; Keech A; Murphy SA; Huber K; Tokgozoglu SL; Lewis BS; Ferreira J; Pineda AL; Somaratne R; Sever PS; Pedersen TR; Sabatine MS
    JAMA Cardiol; 2017 Dec; 2(12):1385-1391. PubMed ID: 29117276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Projected Impact of Population-Wide Achievement of LDL Cholesterol <70 mg/dL on the Number of Recurrent Events Among US Adults with ASCVD.
    McKinley EC; Bittner VA; Brown TM; Chen L; Exter J; Farkouh ME; Huang L; Jackson EA; Levitan EB; Orroth KK; Reading SR; Rosenson RS; Safford MM; Woodward M; Muntner P; Colantonio LD
    Cardiovasc Drugs Ther; 2023 Feb; 37(1):107-116. PubMed ID: 34599698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relation of First and Total Recurrent Atherosclerotic Cardiovascular Disease Events to Increased Lipoprotein(a) Levels Among Statin Treated Adults With Cardiovascular Disease.
    Wong ND; Zhao Y; Sung J; Browne A
    Am J Cardiol; 2021 Apr; 145():12-17. PubMed ID: 33454339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evolving Management of Low-Density Lipoprotein Cholesterol: A Personalized Approach to Preventing Atherosclerotic Cardiovascular Disease Across the Risk Continuum.
    Wilkinson MJ; Lepor NE; Michos ED
    J Am Heart Assoc; 2023 Jun; 12(11):e028892. PubMed ID: 37260036
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduction of C-reactive protein, low-density lipoprotein cholesterol, and its relationship with cardiovascular events of different lipid-lowering therapies: A systematic review and meta-analysis of randomized controlled trials.
    Yang W; Cai X; Lin C; Lv F; Zhu X; Han X; Ji L
    Medicine (Baltimore); 2022 Sep; 101(37):e30563. PubMed ID: 36123891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum Low-Density Lipoprotein Cholesterol and Cardiovascular Disease Risk Across Chronic Kidney Disease Stages (Data from 1.9 Million United States Veterans).
    Hashemi L; Hsiung JT; Arif Y; Soohoo M; Jackson N; Gosmanova EO; Budoff M; Kovesdy CP; Kalantar-Zadeh K; Streja E
    Am J Cardiol; 2022 May; 170():47-55. PubMed ID: 35300833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal low density lipoprotein cholesterol goal achievement and cardiovascular outcomes among adult patients with familial hypercholesterolemia: The CASCADE FH registry.
    Duell PB; Gidding SS; Andersen RL; Knickelbine T; Anderson L; Gianos E; Shrader P; Kindt I; O'Brien EC; McCann D; Hemphill LC; Ahmed CD; Martin SS; Larry JA; Ahmad ZS; Kullo IJ; Underberg JA; Guyton J; Thompson P; Wilemon K; Roe MT; Rader DJ; Cuchel M; Linton MF; Shapiro MD; Moriarty PM; Knowles JW
    Atherosclerosis; 2019 Oct; 289():85-93. PubMed ID: 31487564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population health management of low-density lipoprotein cholesterol via a remote, algorithmic, navigator-executed program.
    Plutzky J; Benson MD; Chaney K; Bui TV; Kraft M; Matta L; McPartlin M; Zelle D; Cannon CP; Dodek A; Gaziano TA; Desai AS; MacRae CA; Scirica BM
    Am Heart J; 2022 Jan; 243():15-27. PubMed ID: 34481756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 2017 Taiwan lipid guidelines for high risk patients.
    Li YH; Ueng KC; Jeng JS; Charng MJ; Lin TH; Chien KL; Wang CY; Chao TH; Liu PY; Su CH; Chien SC; Liou CW; Tang SC; Lee CC; Yu TY; Chen JW; Wu CC; Yeh HI;
    J Formos Med Assoc; 2017 Apr; 116(4):217-248. PubMed ID: 28242176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Twenty-year epidemiologic study on LDL-C levels in relation to the risks of atherosclerotic event, hemorrhagic stroke, and cancer death among young and middle-aged population in China.
    Zhang X; Liu J; Wang M; Qi Y; Sun J; Liu J; Wang Y; Hao Y; Li Y; Zhou M; Zhao D
    J Clin Lipidol; 2018; 12(5):1179-1189.e4. PubMed ID: 30037589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.